US Patent 11945872 Anti-ACVR1 antibodies and uses thereof
Patent 11945872 was granted and assigned to Regeneron Pharmaceuticals on April, 2024 by the United States Patent and Trademark Office.
All edits
Edits on 4 Apr, 2024
Golden AI
Edits made to:
Infobox (+18 properties)
Article (+511 characters)
US Patent 11945872 Anti-ACVR1 antibodies and uses thereof
Article
Patent abstract
The present invention provides monoclonal antibodies that bind to the Activin A type I receptor (ACVR1) protein, and methods of use thereof. In various embodiments of the invention, the antibodies are fully human antibodies that bind to ACVR1. In some embodiments, the antibodies of the invention are useful for inhibiting ACVR1-mediated bone morphogenetic protein (BMP) signal transduction, thus providing a means of treating or preventing a disease, disorder or condition associated with ACVR1.
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
Patent Inventor Names
Aris N. Economides0
Sarah J. Hatsell0
Vincent J. Idone0
Date of Patent
April 2, 2024
0Patent Application Number
171728560
Date Filed
February 10, 2021
0Patent Citations
Patent Primary Examiner
Find more entities like US Patent 11945872 Anti-ACVR1 antibodies and uses thereof
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.